As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Ben Hargreaves
Advertisement
Ben Hargreaves is a freelance science journalist based in Tosse, France.
Articles by Ben Hargreaves
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Viatris Acquires Pacira BioSciences for $1.65 Billion
2
Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
3
ESC 2026: GLP-1–Based Therapies Move Further into Mainstream Cardiovascular Care
4
Pharmaceutical Executive Daily: Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher
5